| Literature DB >> 33344428 |
Guido Caluori1,2,3, Eva Odehnalova1, Tomasz Jadczyk1,4, Martin Pesl1,5,6, Iveta Pavlova7, Lucia Valikova8, Steffen Holzinger9, Veronika Novotna1,10, Vladimir Rotrekl1,5, Ales Hampl1,11, Michal Crha8, Dalibor Cervinka10, Zdenek Starek1,6.
Abstract
INTRODUCTION: Pulsed field ablation (PFA) exploits the delivery of short high-voltage shocks to induce cells death via irreversible electroporation. The therapy offers a potential paradigm shift for catheter ablation of cardiac arrhythmia. We designed an AC-burst generator and therapeutic strategy, based on the existing knowledge between efficacy and safety among different pulses. We performed a proof-of-concept chronic animal trial to test the feasibility and safety of our method and technology.Entities:
Keywords: atrial fibrillation; irreversible electroporation (IRE); preclinical cardiology; pulsed field ablation; radiofrequency ablation; ventricular arrhythmia (VA)
Year: 2020 PMID: 33344428 PMCID: PMC7744788 DOI: 10.3389/fbioe.2020.552357
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Schematic of the electronics configuration. (A) Bipolar catheter electrodes pairings in the atrial and ventricular configuration. The electric fields internal to the loop (left) are not shown for clarity of the figure. (B) Simplified schematic of the electric circuits formed in the operating table, when employing the ventricular configuration. Parasitic circuits are present through the table to the common ground, and the return electrode favors a low impedance/current density pathway on the lower back avoiding capture of the upper limbs into muscle twitching.
FIGURE 2Procedural imaging and electrophysiological results. (A) Circular catheter positioning before pulmonary vein ostium ablation; (B) Circular catheter positioning before atrial wall ablation; (C) catheter positioning across the interventricular septum before ablation; (D) atrial electrograms before (red continuous circle) and after (red dashed circle) ablation; (E) ventricular electrograms before (green, on left ventricle, and orange, on right ventricle, continuous circle) and after (dashed circles) ablation; (F) atrial electrograms changes upon ablation (****p < 0.0001); (G) ventricular electrograms changes upon ablation (****p < 0.0001). LA = left atrium; IVS = interventricular septum, EGM = electrogram.
Electrophysiological parameters changes upon ablation.
| Application | EGM amplitude pre-ablation (mV) | EGM amplitude post-ablation (mV) | EGM duration pre-ablation (ms) | EGM duration post-ablation (ms) | |
| 2.20 ± 0.84 | 0.61 ± 0.18 | 45.29 ± 8.1 | 58.38 ± 12.61 | <0.0001 | |
| 1.95 ± 0.63 | 1.02 ± 0.41 | 38.20 ± 5.894 | 75.62 ± 12.70 | <0.0001 |
FIGURE 3Models and notable results of numerical simulations. (A) Geometry of the pulmonary vein ostium ablation; (B) Geometry of the interventricular septum ablation, with perfect alignment; (C) Electric field variation across the circular catheter used in the left atrium; (D) Average electric field across the interventricular septum, with respect to the relative linear misalignment or angular tilting (*p < 0.05); (E) current density profile in pulmonary vein ostium ablation; (F) current density profile in the interventricular septum ablation in perfect alignment; (G) Temperature profile across the circular catheter used in the left atrium; (H) temperature profile across the interventricular septum upon ablation, with respect to the relative linear misalignment or angular tilting.
Notable results of the electrothermal simulations.
| Model | Voltage applied (V) | Electric field max (kV/cm) | Electric field mean (V/cm) | Current density mean (kA/m2) | Current density max (kA/m2) | Temperature max at the interface (°C) |
| 900 | 5.19 | 0.95 | 47.32 | 361.52 | 40.11 | |
| 900 | 2.19 | 0.48 | 40.37 | 317.55 | 40.19 | |
| 1500 | 4.84 | 1.97 | 56.01 | 127.57 | 39.13 |
FIGURE 4Atrial findings at the end of follow-up. (A) Epicardial circular discoloration observed on the left atrium; (B) diffuse endocardial discoloration in proximity of the pulmonary veins; (C) Posterior view of the 3D rendering of the manual segmentation of normal myocardium (red) and non-myocardial tissue (green), with white arrows pointing at pulmonary vein ostia; (D) Posterior view of the 3D rendering of an age-matched non-ablated control, segmented with same criteria; (E) trichrome staining of left atrium which underwent AC pulsed electric field ablation, showing circular continuous and transmural lesions; (F) trichrome staining of age-matched non-ablated control. Scalebar is 3 mm.
Volumetric ratio of the non-myocardial tissue as calculated from manual segmentation of the 9.4T MRI atrial scans.
| AC-PFA#1 | AC-PFA#2 | AC-PFA#3 | AC-PFA#4 | AC-PFA#5 | CTL | |
| Non-myocardial volume percentage | ||||||
| 70.34 ± 21.98 | 78.49 ± 16.41 | 81.77 ± 12.17 | 82.71 ± 11.36 | 82.61 ± 12.40 | 90.77 ± 6.164 | |
| <0.0001 | 0.0010 | 0.0075 | 0.0100 | 0.0158 | NA | |
FIGURE 5Ventricular findings at the end of follow-up. (A) Ex vivo T1 axial scans with highlighted changes identified with AC pulsed field ablation lesions (red dotted lines) – in the inset it is visible a control RF ablation lesion. Scale bar is 10 mm; (B) Posterior view of the 3D rendering of ventricular myocardial perimeter (red), AC pulsed field ablation lesions (green) and RF ablation lesions (yellow); (C) trichrome staining of apical transmural lesions across the interventricular septum; (D) trichrome staining of basal isolated AC pulsed electric field ablation lesion, with intact core of cardiomyocytes.